Binh Dinh Pharmaceutical and Medical Equipment Past Earnings Performance
Past criteria checks 4/6
Binh Dinh Pharmaceutical and Medical Equipment has been growing earnings at an average annual rate of 13.1%, while the Pharmaceuticals industry saw earnings growing at 12.4% annually. Revenues have been growing at an average rate of 5.9% per year. Binh Dinh Pharmaceutical and Medical Equipment's return on equity is 18.8%, and it has net margins of 14%.
Key information
13.1%
Earnings growth rate
13.1%
EPS growth rate
| Pharmaceuticals Industry Growth | 13.0% |
| Revenue growth rate | 5.9% |
| Return on equity | 18.8% |
| Net Margin | 14.0% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Binh Dinh Pharmaceutical and Medical Equipment makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 1,651,770 | 231,387 | 501,538 | 0 |
| 30 Sep 23 | 1,688,916 | 235,825 | 514,645 | 0 |
| 30 Jun 23 | 1,654,996 | 238,441 | 509,387 | 0 |
| 31 Mar 23 | 1,577,853 | 226,700 | 494,721 | 0 |
| 31 Dec 22 | 1,554,821 | 209,457 | 494,312 | 0 |
| 30 Sep 22 | 1,494,595 | 181,011 | 457,406 | 0 |
| 30 Jun 22 | 1,654,406 | 168,156 | 465,740 | 0 |
| 31 Mar 22 | 1,628,301 | 175,687 | 443,770 | 0 |
| 31 Dec 21 | 1,558,504 | 162,646 | 405,437 | 0 |
| 30 Sep 21 | 1,500,950 | 144,547 | 377,439 | 0 |
| 30 Jun 21 | 1,224,917 | 151,994 | 319,057 | 0 |
| 31 Mar 21 | 1,165,758 | 136,014 | 284,755 | 0 |
| 31 Dec 20 | 1,256,952 | 138,916 | 309,356 | 0 |
| 30 Sep 20 | 1,310,512 | 152,680 | 303,594 | 0 |
| 30 Jun 20 | 1,341,568 | 136,409 | 295,366 | 0 |
| 31 Mar 20 | 1,389,839 | 134,560 | 314,776 | 0 |
| 31 Dec 19 | 1,261,729 | 128,005 | 254,046 | 0 |
| 30 Sep 19 | 1,251,065 | 124,796 | 236,974 | 0 |
| 30 Jun 19 | 1,309,152 | 137,586 | 215,640 | 0 |
| 31 Mar 19 | 1,304,700 | 140,059 | 210,734 | 0 |
| 31 Dec 18 | 1,401,024 | 146,704 | 241,571 | 0 |
| 30 Sep 18 | 1,400,268 | 155,163 | 253,230 | 0 |
| 30 Jun 18 | 1,382,479 | 153,894 | 277,045 | 0 |
| 31 Mar 18 | 1,393,974 | 147,133 | 293,798 | 0 |
| 31 Dec 17 | 1,388,227 | 147,952 | 303,734 | 0 |
| 30 Sep 17 | 1,383,637 | 144,064 | 314,236 | 0 |
| 30 Jun 17 | 1,383,273 | 132,605 | 324,620 | 0 |
| 31 Mar 17 | 1,380,066 | 136,230 | 327,957 | 0 |
| 31 Dec 16 | 1,384,902 | 125,049 | 351,190 | 0 |
| 30 Sep 16 | 1,351,117 | 95,443 | 367,361 | 0 |
| 30 Jun 16 | 1,312,923 | 102,804 | 353,480 | 0 |
| 31 Mar 16 | 1,297,638 | 102,753 | 371,573 | 0 |
| 31 Dec 15 | 1,225,068 | 188,618 | 324,114 | 0 |
| 31 Dec 14 | 1,370,460 | 48,840 | 202,816 | 0 |
Quality Earnings: DBD has high quality earnings.
Growing Profit Margin: DBD's current net profit margins (14%) are higher than last year (13.5%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: DBD's earnings have grown by 13.1% per year over the past 5 years.
Accelerating Growth: DBD's earnings growth over the past year (10.5%) is below its 5-year average (13.1% per year).
Earnings vs Industry: DBD earnings growth over the past year (10.5%) exceeded the Pharmaceuticals industry -2.4%.
Return on Equity
High ROE: DBD's Return on Equity (18.8%) is considered low.